Find the right fit for you - faster
Get tailored insights about working at Fate Therapeutics in one quick step.
Fate Therapeutics Snapshot
We are pioneering the pharmacological programming of cell function and fate and are dedicated to the development of disruptive cellular immunotherapies for patients with cancer and immune diseases.
We believe that better cell therapies start with better cells. To produce better cell therapies, we apply our proprietary iPSC product platform to create multiplexed-engineered, clonal master iPSC lines having preferred biological properties.
Clonal master iPSC lines can be used as a renewable cell source to manufacture cell therapy products that can be delivered off-the-shelf to treat many patients. Our cells of interest are the cells of the immune system. And our cell therapy product candidate pipeline is comprised of natural killer (NK) cell and T-cell product candidates.
We believe that better cell therapies start with better cells. To produce better cell therapies, we apply our proprietary iPSC product platform to create multiplexed-engineered, clonal master iPSC lines having preferred biological properties.
Clonal master iPSC lines can be used as a renewable cell source to manufacture cell therapy products that can be delivered off-the-shelf to treat many patients. Our cells of interest are the cells of the immune system. And our cell therapy product candidate pipeline is comprised of natural killer (NK) cell and T-cell product candidates.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s effector cell pipeline includes multiplexed-engineered, iPSC-derived natural killer (NK) cell and T-cell product candidates, which incorporate novel synthetic controls of cell function, such as chimeric antigen receptors (CARs) to target tumor-associated antigens and are intended to deliver multiple mechanisms of therapeutic importance to patients including in combination with well-established cancer therapies. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
